Prostate-specific membrane antigen-targeting theranostics in neuroendocrine neoplasms – Initial results from the GI-PSMA phase II trial

#4078

Introduction: A single-center Phase II trial (“GI-PSMA”, NCT05547919) was conducted to evaluate prostate-specific membrane antigen (PSMA)-targeted theranostics in gastroenteropancreatic tumors.

Aim(s): To report on initial results of the GI-PSMA trial in the subgroup of gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN).

Materials and methods: We report on 11 patients affected with GI-NEN (grade 1, 1/11 [9%]; grade 2, 5/11 [45.5%]; grade 3, 2/11 [18.2%]; neuroendocrine carcinoma [NEC], 3/11 [27.3%]). All patients were treatment-naive and underwent PSMA-directed PET/CT using [18F]PSMA-1007 and [18F]FDG upon initial staging. We then revealed the diagnostic performance of PSMA-PET/CT on a patient- and lesion-based level and conducted quantification of uptake in sites of disease. The therapeutic potential of PSMA-targeted radioligand therapy (RLT) was evaluated using dosimetry over 96h in additional three advanced NEN patients, which had exhausted all other treatment options.

Conference:

Presenting Author: Weich A

Authors: Weich A, Serfling S, Bayer J, Buck A, Bley T,

Keywords: neuroendocrine, PSMA-PET/CT, dosimetry, high-grade NEN, PSMA,